Results 51 to 60 of about 2,604,331 (176)

Quickly evolving near‐infrared photoimmunotherapy provides multifaceted approach to modern cancer treatment

View, 2022
Among modalities of cancer immunotherapy, near‐infrared photoimmunotherapy (NIR‐PIT) has reached significant preclinical and clinical stages and quickly evolved over the last 5 years.
Hailey Monaco, Shinya Yokomizo, Hak Soo Choi, Satoshi Kashiwagi   +3 more
doaj   +1 more source

ALDH Inhibition‐Primed Photocatalysis Disrupts Cancer Stemness Plasticity

Angewandte Chemie, EarlyView.
DE‐Et converts ALDH‐mediated redox buffering into a photoredox vulnerability by coupling ALDH inhibition with red‐light‐driven catalytic NADH oxidation. This enzyme‐coupled photoredox strategy sustains mitochondrial NADH/NAD+ imbalance, induces pyroptotic tumor cell death, suppresses tumor growth in vivo, and promotes systemic antitumor immunity ...
Yujin Kim, Shankun Yao, Ji Hyeon Kim, Rongrong Huang, Hyeonji Rha, Shumeng Li, Kippeum Lee, Yunjie Xu, Xiaogang Liu, Yuncong Chen, Jong Seung Kim   +10 more
wiley   +2 more sources

Near infrared photoimmunotherapy with an anti-mesothelin antibody

Oncotarget, 2016
Near Infrared-Photoimmunotherapy (NIR-PIT) is a new, highly selective tumor treatment that employs an antibody-photon absorber conjugate (APC). When the APC attaches to its target cell and is exposed to NIR light, highly selective cell killing is observed. NIR-PIT has been demonstrated with a limited number of antibodies. Mesothelin is overexpressed in
Nagaya, Tadanobu, Nakamura, Yuko, Sato, Kazuhide, Zhang, Yi-Fan, Ni, Min, Choyke, Peter L., Ho, Mitchell, Kobayashi, Hisataka   +7 more
openaire   +3 more sources

Gas therapy potentiates aggregation-induced emission luminogen-based photoimmunotherapy of poorly immunogenic tumors through cGAS-STING pathway activation

Nature Communications, 2023
The immunologically “cold” microenvironment of triple negative breast cancer results in resistance to current immunotherapy. Here, we reveal the immunoadjuvant property of gas therapy with cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS ...
Kaiyuan Wang, Yang Li, Xia Wang, Zhijun Zhang, Liping Cao, Xiaoyuan Fan, Bin Wan, Fengxiang Liu, Xuanbo Zhang, Zhonggui He, Yingtang Zhou, Dong Wang, Jin Sun, Xiaoyuan Chen   +13 more
doaj   +1 more source

Pathological features of residual head and neck cancer after near-infrared photoimmunotherapy: implications of an unfavorable tumor immune microenvironment

Photodiagnosis and Photodynamic Therapy
Purpose: Near-infrared photoimmunotherapy has been approved in Japan for unresectable locally advanced or recurrent head and neck cancer. While this therapy theoretically induces selective necrosis of epidermal growth factor receptor-expressing tumor ...
Takuma Makino, Yasuharu Sato, Asami Nishikori, Yuto Naoi, Mizuo Ando   +4 more
doaj   +1 more source

Optimal Light Dose for hEGFR-Targeted Near-Infrared Photoimmunotherapy

Cancers, 2022
Near-infrared photoimmunotherapy (NIR-PIT) is a newly developed cancer therapy that targets cancer cells using a monoclonal antibody-photon absorber conjugate (APC) that is bound to the target cell surface. Subsequent application of low levels of NIR light results in immediate cancer cell death.
Hideyuki Furumoto, Ryuhei Okada, Takuya Kato, Hiroaki Wakiyama, Fuyuki Inagaki, Hiroshi Fukushima, Shuhei Okuyama, Aki Furusawa, Peter L. Choyke, Hisataka Kobayashi   +9 more
openaire   +2 more sources

Theranostic Near-Infrared Photoimmunotherapy [PDF]

, 2019
Near-infrared photoimmunotherapy (NIR-PIT) is a newly developed cell-selective cancer therapy with enormous potential for treating cancer in a variety of ways. NIR-PIT not only kills cancer cells, but can also eliminate other unfavorable cells including cancer stem cells and immune-suppressor cells, among others, without damaging favorable cells such ...
openaire   +1 more source

Near-Infrared Photoimmunotherapy for Treatment of Colorectal Cancer in Orthotopic Nude-Mouse Models

, 2020
Background: Photoimmunotherapy (PIT) employs the use of near-infrared (NIR) laser to activate an antibody conjugated to a NIR-activatable dye to promote cancer cell death. PIT has shown to be effective in a number of studies, however, there is no data on
Filemoni Filemoni (8649674), Michael Bouvet (8649681), Siamak Amirfakhri (8649675), Paul Yazaki (8649684), Robert M. Hoffman (8649682), Justin Molnar (8649678), Hannah Hollandsworth (8276115)   +6 more
core   +1 more source

Antibody Drug Conjugates of Near-Infrared Photoimmunotherapy (NIR-PIT) in Breast Cancers

Technology in Cancer Research & Treatment, 2023
Worldwide, the incidence rate of breast cancer is the highest in women. Approximately 2.3 million people were newly diagnosed and 0.685 million were dead of breast cancer in 2020, which continues to grow.
Yingshu Cui BD, Yuanyuan Xu BD, Yi Li BD, Yuanyuan Sun BD, Jia Hu MD, Jia Jia BD, Xiaosong Li MD   +6 more
doaj   +1 more source

Recent Advances in Localized Immunomodulation Technology: Application of NIR-PIT toward Clinical Control of the Local Immune System

Pharmaceutics, 2023
Current immunotherapies aim to modulate the balance among different immune cell populations, thereby controlling immune reactions. However, they often cause immune overactivation or over-suppression, which makes them difficult to control.
Mizuki Yamada, Kohei Matsuoka, Mitsuo Sato, Kazuhide Sato   +3 more
doaj   +1 more source